Welcome to our dedicated page for VSEE HEALTH SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. has set its 2026 annual meeting of stockholders for August 25, 2026. Stockholders of record as of July 6, 2026 will be entitled to receive notice of and vote at the meeting. Additional details on the time, location and agenda will appear in the company’s proxy statement.
To present stockholder proposals at the meeting or seek inclusion under Rule 14a-8, the company must receive proper notice at its Boca Raton headquarters by the close of business on July 17, 2026. The same July 17, 2026 deadline applies for proposals affecting discretionary voting under Rule 14a-4(c), as well as for business brought under the company’s by-laws and notices required under the universal proxy rules, including Rule 14a-19 for alternative director nominees.
VSee Health, Inc. entered into two unsecured convertible note financings with institutional investors, raising aggregate principal of $280,000 from ClearThink and $295,550 from Vanquish, each including an original issue discount. The ClearThink note carries a one-time 10% interest charge, matures on June 22, 2027, and becomes convertible after 180 days at 85% of the lowest closing price over the prior ten trading days, with a $0.01 floor and a 4.99% beneficial ownership cap.
The Vanquish note carries a one-time 12% interest charge, matures on April 15, 2027, and is convertible after the later of 180 days from issuance or an Event of Default at 75% of the lowest closing bid price over the prior ten trading days, also subject to a 4.99% beneficial ownership cap. Both notes were issued in private placements exempt from registration under Section 4(a)(2) and/or Regulation D.
VSee Health, Inc. filed a prospectus supplement and attached Form 8-K to update a resale registration that covers up to 33,808,195 shares of Common Stock. The registered shares comprise 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares, 9,836,065 Armistice pre-funded warrant shares and 19,672,130 Armistice warrant shares. The supplement incorporates a Form 8-K reporting receipt of a notice claiming an Event of Default under an 8% original issue discount secured promissory note in the aggregate principal amount of $271,739.13; the company is evaluating resolution alternatives.
VSee Health, Inc. reports that noteholder ADI Funding, LLC has delivered a notice asserting an Event of Default under an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, including an original issue discount of $21,739.13.
The holder’s notice alleges the company failed to meet several obligations tied to a June 8, 2026 securities purchase agreement, including filing a resale registration statement and issuing transfer agent instructions by June 11, 2026. Under the note, VSee Health has ten Trading Days from the Event of Default to cure. If not cured, the holder may accelerate the debt, enforce collateral rights, seek payment of all amounts due including any Mandatory Default Amount, and recover attorneys’ fees and costs. The company is evaluating potential resolution alternatives, including a consensual resolution, while expressly preserving all of its rights, remedies and defenses.
VSee Health, Inc. filed a prospectus supplement registering for resale up to 33,808,195 shares of Common Stock by named selling stockholders, including 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. The supplement incorporates Form 8-K disclosure of a Standby Equity Purchase Agreement dated June 2, 2026 under which YA II PN, LTD. commits up to $10,000,000 in purchase capacity through June 2, 2029, subject to a Nasdaq Exchange Cap of 9,715,140 shares (approximately 19.99%) and an ownership limit of 4.99%. Pricing under the SEPA is set at 97% of the lowest daily VWAP during a three-consecutive trading day Pricing Period. The prospectus supplement and Prospectus govern resale mechanics; proceeds treatment is for selling stockholders.
VSee Health, Inc. entered into a high-interest note financing with an institutional investor. The company issued an 8% original issue discount secured promissory note with an aggregate principal amount of $271,739.13, which includes an original issue discount of $21,739.13. The note bears interest at 18% per annum and matures on December 8, 2026.
The company may prepay all or part of the note at 100% of the amount redeemed plus a 10% prepayment fee. If VSee receives proceeds from an equity line of credit with the same holder, it must repay the entire outstanding balance within two business days. The note is secured by certain company assets under a related security agreement.
VSee Health, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., giving the company the right to sell up to $10 million of common stock over time. The arrangement runs until June 2, 2029, unless the full commitment is used or it is terminated earlier.
Shares sold under each Advance will be priced at 97% of the lowest daily VWAP over a three-day pricing period. VSee will issue 532,481 commitment shares and pay a $25,000 structuring fee from the first Advance. Issuances are capped at 9,715,140 shares, about 19.99% of pre-agreement outstanding shares, and the investor’s beneficial ownership is limited to 4.99%.
VSee Health, Inc. filed a prospectus supplement registering the resale of up to 33,808,195 shares of Common Stock.
The supplement breaks that aggregate into 3,000,000 Manatt Shares; up to 1,300,000 Series B Shares; 9,836,065 pre-funded warrant shares; and 19,672,130 warrant shares. The supplement attaches a Form 8-K describing the sale of VSee Lab to Milton Chen, who agreed to transfer 2,870,069 shares of Common Stock back to the company and resigned as co-CEO and chair; Dr. Imoigele Aisiku is now sole CEO and chair. The common stock last reported at $0.1570 per share on Nasdaq on June 9, 2026.
VSee Health, Inc. agreed to sell all of the equity of its wholly owned subsidiary VSee Lab, Inc. to co-Chief Executive Officer and Chairman Milton Chen, effective May 31, 2026. In return, Chen will transfer to the company all 2,870,069 shares of VSee Health common stock he owns, which are treated as a stock repurchase.
Under the agreement, Chen is solely responsible for indebtedness and other liabilities of VSee Lab not paid at closing, while VSee Health remains responsible for liabilities tied to periods on or before the closing date, including most taxes. Concurrent with closing, Chen resigned as co-Chief Executive Officer and chairman; co-CEO Dr. Imoigele Aisiku became sole Chief Executive Officer and chairman.
Unaudited pro forma financials show how results would look without VSee Lab and its subsidiary. For 2025, revenue would decline from $14,618,184 to $7,302,954, while net loss would narrow from $14,712,850 to $9,972,749. For the quarter ended March 31, 2026, revenue would fall from $3,160,185 to $1,879,293 and net loss would narrow from $2,600,262 to $1,264,882.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.